In the National Cancer Plan, the government has published its plan to transform cancer care and outcomes in England by 2035.
Earlier diagnosis and quicker treatment are being promised by ministers. The plan’s ambition promises the fastest improvement in cancer outcomes this century.
The latest data of 2022 reflect a 5-year survival rate of 60%. This leaves the UK lagging behind other developed countries.
To achieve this goal, the government has pledged to reduce the 62-day waiting time target within the next 3 years by 2029. The government has now met this target for more than a decade.
Experts believe that it may require significant extra investment. This warning cited the need for more staff to make improvements.
The NHS budget would likely bear the cost of the government’s drug pricing deal with the Trump administration. Instead of the Treasury’s budget, campaigners have warned that it could eventually reach USD 12.24 (£ 9) billion annually.
The science minister, Patrick Vallance, has confirmed that the costs would initially be an extra USD 1.32 (£ 1) billion, spanning 3 years. The Department of Health and Social Care, which funds the NHS in England, would bear this cost, not the Treasury.
Vallance’s admission came in a letter to the Commons Science, Innovation, and Technology Select Committee.
Director of policy, Dr. Layla McCay, speaking on behalf of the NHS Confederation & NHS Providers, said that the health leaders will be concerned to note that, against an already very challenging financial environment, DHSC budgets will need to be deployed. She added that it also remains unclear which planned DHSC spending will need to be reduced to cover the costs of higher medicine expenditure.
In a new survey of nurses, midwives, and nursing associates by the Nursing and Midwifery Council (NMC), it has been revealed that over half of respondents (58%) are satisfied in their work.
